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Usually, primary hyperparathyroidism is the first endocrinopathy to be diagnosed in patients with multiple
endocrine neoplasia type 1, and is also the most common one. The timing of the surgery and strategy in multiple
endocrine neoplasia type 1/hyperparathyroidism are still under debate. The aims of surgery are to: 1) correct
hypercalcemia, thus preventing persistent or recurrent hyperparathyroidism; 2) avoid persistent hypoparathyroid-
ism; and 3) facilitate the surgical treatment of possible recurrences. Currently, two types of surgical approach are
indicated: 1) subtotal parathyroidectomy with removal of at least 3–3K glands; and 2) total parathyroidectomy with
grafting of autologous parathyroid tissue. Transcervical thymectomy must be performed with both of these
procedures. Unsuccessful surgical treatment of hyperparathyroidism is more frequently observed in multiple
endocrine neoplasia type 1 than in sporadic hyperparathyroidism. The recurrence rate is strongly influenced by: 1)
the lack of a pre-operative multiple endocrine neoplasia type 1 diagnosis; 2) the surgeon’s experience; 3) the timing
of surgery; 4) the possibility of performing intra-operative confirmation (histologic examination, rapid parathyroid
hormone assay) of the curative potential of the surgical procedure; and, 5) the surgical strategy. Persistent
hyperparathyroidism seems to be more frequent after subtotal parathyroidectomy than after total parathyr-
oidectomy with autologous graft of parathyroid tissue. Conversely, recurrent hyperparathyroidism has a similar
frequency in the two surgical strategies. To plan further operations, it is very helpful to know all the available data
about previous surgery and to undertake accurate identification of the site of recurrence.
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INTRODUCTION
Usually, primary hyperparathyroidism (HPT) is the first
endocrinopathy to be diagnosed in patients with multiple
endocrine neoplasia type 1 (MEN1), and is the most
common one (1). The optimal surgical timing and strategy
in HPT/MEN1 are still under debate. The aims of surgery
are to: correct hypercalcemia, and thus prevent persistent or
recurrent hyperparathyroidism; avoid persistent hypopar-
athyroidism; and facilitate the surgical treatment of possible
recurrences. Currently, two types of surgical approaches are
indicated: subtotal parathyroidectomy (SPTX) with removal
of at least 3–3.5 glands; and total parathyroidectomy with
autologous graft of parathyroid tissue (TPTX). Transcervical
thymectomy must be performed with both procedures.
However, controlled clinical trials comparing SPTX and
TPTX are lacking. Review of the published surgical data
shows that persistent HPT is more frequent after SPTX than
after TPTX, and recurrent hyperparathyroidism has a
similar percentage in both surgical options. The recurrence
rate is strongly influenced by the lack of a pre-operative
diagnosis of MEN1, the surgeon’s experience, the timing
of the surgery, and the possibility of performing intra-
operative confirmation [histologic examination and rapid
parathyroid hormone (PTH) assay] of the potential curative
capacity of the surgical procedure. To plan further opera-
tions, it is very helpful to have all the available data about
previous surgery and to undertake accurate identification of
the possible site of the recurrence.
Penetrance in HPT/MEN1 is nearly 100% at the age of 50
years; the age of onset of biochemical alteration is usually
20–25 years (2).
As in sporadic HPT, diagnosis is usually prompted by the
presence of hypercalcemia, with elevated serum levels of
ionized calcium and PTH. Parathyroid gland involvement
in MEN1 is asynchronous and asymmetrical; the change in
volume varies, but the maximum/minimum mean volume
ratio is 9.6 (3). Macroscopically normal parathyroid glands
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make up 12–55% of all glands; sometimes the intra-operative
findings may consist of just one or two enlarged glands (4–6).
Moreover, the frequency of supernumerary glands (up to
20% in HPT/MEN1) (6,7) and of ectopic glands (often
intrathymic, within the thyroid gland, in the anterior
mediastinum) is higher than expected (5,8). Some reports
describe the presence of parathyroid nests (embryonic
parathyroid rests, a direct result of ontogenesis) embedded
within the fatty tissue surrounding the trachea, esophagus,
and carotid artery (8–11). Genetic testing is the gold standard
to confirm diagnosis of MEN1, and should be performed in
any young patient with hyperparathyroidism, even in the
absence of a clear familial history of MEN1 syndrome.
Timing of surgery
The optimal timing for surgery in HPT/MEN1 is still
under debate. It is possible to follow the same indications
used for sporadic HPT, taking into account that cases of
HPT/MEN1 often have only mildly elevated calcium and
PTH levels. However, even when MEN1-related HPT has a
long asymptomatic phase, it is important to note that it is
the cause of a detectable bone mass decrease at a young age
(12). Correction of hypercalcemia by prompt intervention is
helpful in patients who show a decrease in bone mineral
density, as it can prevent renal complications and may be of
benefit for other concomitant endocrinopathies, such as
hypergastrinemia (13).
In the case of concomitant multiple endocrinopathies in
patients with HPT/MEN1, there is agreement among
authors on the need to treat the HPT first, with the
exception of cases of insulinoma.
Surgical strategy
The aims of surgery are to correct hypercalcemia,
preventing persistent or recurrent HPT; avoid persistent
hypoparathyroidism; and facilitate the surgical treatment of
possible recurrences.
Less than subtotal parathyroidectomy, with removal of
enlarged glands only, is associated with a high persistence/
recurrence rate, so it is no longer used for diagnosed MEN1-
HPT. Therefore, two surgical approaches are in routine use:
SPTX, with removal of at least 3–3.5 glands, or TPTX.
Transcervical thymectomy must be performed with both
procedures as the thymus can harbor an ectopic parathyroid
gland; thymectomy is also helpful in preventing thymic
carcinoids possibly arising during the evolution of the
syndrome.
Subtotal parathyroidectomy (SPTX). SPTX is defined as
the removal of three glands and part of the fourth (usually
the least involved one), preserving not more than 50 mg of
parathyroid tissue. The fourth gland can also be completely
preserved if normal in volume. SPTX is used with the main
aim of avoiding permanent hypoparathyroidism and also of
reducing the risk of early postoperative hypocalcemia.
SPTX becomes the surgical choice when a fourth para-
thyroid cannot be found out during surgery. This occurs in
up to 20% of cases, even when treatment occurs in
specialized centers (14,15). Nevertheless, there are many
criticisms leveled at SPTX as, in most cases, all the
parathyroid glands are found to be pathologic and it is
difficult to establish which of them is less involved and can
be preserved.
Furthermore, it can be difficult to preserve enough
parathyroid tissue, particularly in the case of small glands.
During this maneuver, the fine parathyroid vessels can
easily be damaged, with consequent permanent hypopar-
athyroidism. In addition, surgery on these potentially
pathologic glands could expose the patient to the risk of
favoring the seeding of parathyroid cells into the nearest
structures, thus favoring cervical recurrence of HPT (16).
All these considerations may explain the poor outcomes
shown in several published studies, with high rates either of
persistent and early recurrent HPT or of hypoparathyroid-
ism (Table 1) (4,5,13–15,17–29).
Table 1 - Results after subtotal parathyroidectomy (SPTX) in multiple endocrine neoplasia type 1 (MEN1)-
hyperparathyroidism (HPT).
Author Year Period Pts
Mean follow-up
(yrs)
Persistent
HPT (%)
Recurrent
HPT (%) Hypoparathyroidism (%)
Edis et al. (23) 1979 1959–76 55 3.9 13 0 35
Prinz et al. (24) 1981 1955–76 12 9.5 33 0 25
Van Heerden et al. (25) 1983 1960–83 45 N.A. 6.6 6.6 13
Goretzki et al. (26) 1991 1986–90 18 N.A. 11 0 0
Hellman et al. (17) 1992 1982–91 11 11.9 0 27.3 27.3
Kraimps et al. (5) 1992 1966–88 14 8 14 36 10
O’ Riordain et al. (15) 1993 1970–91 54 10 0 16.4* 8
Janson et al. (18) 1994 1971–92 4 9.9 0 25 0
Thompson et al. (27) 1994 1972–92 14 20 7 7 0
Grant at al. (28) 1994 1980–93 15 4.7 0 13.3 0
Nilsson et al. (19) 1994 1971–92 2 9 0 0 0
Hellman et al. (20) 1998 1969–96 9 7.3 22 44 0
Goudet et al. (14) 2001 1986–97 73 N.A. 16.8 N.A. N.A.
Dotzenrath et al. (21) 2001 1986–98 25 10 N.A. 8* 12
Arnalsteen et al. (4) 2002 1992–01 66 10 N.A. 33* 12.7
Elaraj et al. (22) 2003 1960–02 63 10 N.A. 51* 26
Hubbard et al. (29) 2006 1974–02 21 5 0 5 10
Norton et al. (13) 2008 1970–05 41 7.9 12 44 10
*Actuarial estimation.
N.A. = not applicable.
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Total parathyroidectomy (TPTX). TPTX consists of total
parathyroidectomy with transcervical thymectomy and
autologous transplantation of parathyroid tissue. The aim
of this technique is to radically remove all the parathyroid
tissue, including the occult gland potentially present within
the thymus and the surrounding fatty tissues, to avoid
cervical recurrences that are difficult to treat, and to reduce
the risk of permanent hypoparathyroidism by means of a
graft, usually in the nondominant forearm.
The graft can be obtained at the end of surgery from
fresh autologous tissue preserved at 4 C˚ in Ringer lactate
solution or days later (once it has been ascertained that the
HPT has been cured) using cryopreserved tissue, using the
technique described by Sonoda et al. (30) and Wells et al.
(31). The tissue to graft should be chosen from the gland
that appears most normal in volume, colour, and texture
after analysis of frozen sections. The graft fragments should
be the smallest possible (around 1 mm3) to facilitate the
graft implant (32). The optimal grafting site is generally the
brachio-radialis muscle of the nondominant forearm. This
procedure will allow monitoring of the success of the
autotransplantation through bilateral blood sampling from
each basilic vein for measurement of PTH levels. After
incision of the fascia of the brachio-radialis muscle, its
fibers are bluntly divided in order to create small spaces in
which to embed 2–3 fragments of parathyroid tissue. The
fascia is then sutured with nonabsorbable wires to mark
the site. The number of fragments that should be grafted is
still under debate, with various recommendations in the
medical literature. Commonly 20–25 fragments (or more in
the case of cryopreserved tissue) are considered the
optimal number (33). Other series report 5–10 transplanted
fragments (23,24), but with higher rates (50–60%) of
nonworking grafts, either with fresh or cryopreserved
parathyroid tissue (Table 2) (13,17–20,22,28–30,33,35,36). It
is still unclear whether the success rate is associated with
the technical procedure or with the parathyroid histo-
pathology.
Interestingly, in the study by Janson and Tisell, no
permanent hypoparathyroidism was seen and rapid para-
thyroid function restoration was observed after grafting
parathyroid tissue within the abdominal subcutaneous fat in
seven patients with MEN1 (18). In the past few years our
center has moved towards implantation of eight fresh
fragments instead of more than 12. This choice did not
increase the number of cases of permanent hypoparathyr-
oidism. We also implanted the autograft in the subcuta-
neous tissue of the nondominant forearm with the same
optimal results. These data support the importance of local
factors (i.e. angiogenesis) for the successful implantation of
the graft (Table 2) (13,17–20,22,28,30,35,36).
Cause of failure of treatment of MEN1-HPT
Unsuccessful surgical treatment of HPT is more fre-
quently observed in MEN1 than in sporadic HPT. Persistent
hypoparathyroidism seems to be more frequent after SPTX
than after TPTX (9% vs. 0.03%), and the cause may be
related to hyperfunctioning parathyroid tissue in the
portion of the gland preserved during SPTX. Conversely,
recurrent hyperparathyroidism has a similar percentage in
the two surgical strategies (18.6% vs. 18.5%); it is strongly
dependent on the length of follow-up, and the cause may be
related to the hyperfunctioning of the tissue if an excessive
amount has been left in place after SPTX, or to the presence
of supernumerary glands in cases treated with TPTX. There
is no evidence in the literature of persistent or recurrent
HPT/MEN1 cases caused by parathyreomatosis, although
such cases have been reported in sporadic primary HPT (1–
2%) and secondary HPT (12%) (37–39).
The recurrence rate is strongly influenced by:
1. Pre-operative diagnosis of MEN 1 significantly reduces
the rate of surgical failures (5,40) and pre-operative
Table 2 - Results after total parathyroidectomy (TPTX) in multiple endocrine neoplasia type 1 (MEN1)-
hyperparathyroidism (HPT).
Author Year Period Pts
Mean
follow-up
(yrs)
Persistent
HPT
(%)
Recurrent
HPT
(%)
Hypoparathyroidism
(%)
Wells et al. (31) 1980 1973–80 36 7 3 30 5.6
Malmaeus et al. (36) 1986 1961–85 18 6.5 0 0 26
Hellman et al. (17) 1992 1982–91 23 6.1 0 22 30
Janson et al. (18) 1994 1971–92 6 9.9 0 0 0
Dralle et al. (35) 1994 1976–92 4 6.3 0 0 50
Nilsson et al. (19) 1994 1971–92 6 9 0 0 0
Hellmann et al. (20) 1998 1969–96 15 10.2 0 20 47
Elaraj et al. (22) 2003 1960–02 16 10 N.A. 16* 46
Hubbard et al. (29) 2006 1974–02 4 14 0 50 25
Norton et al. (13) 2008 1970–05 9 9.9 0 55 22
Tonelli et al. (6) 2007 1990–06 45 6.5 0 11 22
*Actuarial estimation.
N.A. = not applicable.
Table 3 - Intraoperative parathyroid hormone (PTH)
monitoring for prediction of multi-glandular parathyroid
disease after removal of the first pathological
parathyroid gland.
Author
Decrease of
intra-operative PTH
from baseline
False positive
percentage*
Clerici et al. (44) .50% at 109 75%
Jaskowiak et al. (45) .50% at 109 50%
Kivlen et al. (43){ .50% at 109 14%
Arnalsteen et al. (4){ .50% at 59 5%
Thompson et al. (46) .70% at 209 0%
*Decrease below the cut-off point in the presence of other enlarged
gland/s.
{Patients with MEN1 only.
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detection of a MEN1 gene mutation is essential when the
clinical history is suggestive of MEN1.
2. HPT/MEN1 persistence rates correlate with the experi-
ence of the surgeon, being significantly lower for surgeons
working centers with high referral rates of HPT (17).
3. The optimal timing of surgery in asymptomatic cases
with mild hypercalcemia is still debated. In fact, postponing
surgery for some patients with MEN1 may increase the
chances of identifying all the involved parathyroid glands,
as over time, they become enlarged, making surgery easier
and more effective.
4. Intra-operative histologic examination is useful to confirm
the presence of parathyroid tissue in the specimen, especially
in doubtful cases when ectopic glands are found. Histologic
confirmation may be of value when grafting fresh parathyroid
tissue is programmed, making it possible to avoid grafting of
fragments of tissue with pathologic histologic features.
5. Rapid intra-operative PTH measurement has become
important in clinical practice to guide the surgery (41,42).
Its sensitivity is reported as nearly 95% in surgical
treatment of sporadic adenoma (4,42,43). When used for
the discrimination of HPT caused by hyperplasia or
multiglandular disease, the rapid intra-operative PTH
assay has shown substantially lower reliability, with a
high rate of false positive values (43–45), probably due to
the presence of glands suppressed (even if potentially
neoplastic) by the most pathologic one. In fact, 10 minutes
after removal of the first pathologic gland, PTH values can
decrease by more than 50% from baseline. Using other
criteria, such as evaluation after 20 minutes and a cut-off of
70%, Thompson et al. did not observe any false positive
cases (Table 3) (46). In our opinion, the main role of
intra-operative PTH should be to confirm removal of all the
parathyroid tissue, so that the search for other parathyroid
glands can be stopped and the graft of fresh parathyroid
tissue performed. In our experience, stepwise venous
sampling after the removal of each parathyroid gland until
the PTH values are almost undetectable (i.e. near to the
sensitivity limit of the PTH assay used) is a reliable method
to confirm effective parathyroidectomy and to indicate that
parathyroid autotransplantation can proceed (Figure 1) (6).
Treatment of persistent and recurrent MEN1-HPT
To plan further operations, it is very helpful to have all
the available data regarding previous surgery and to
undertake an accurate localization of the site of recurrence.
If a forearm graft is present, circulating PTH levels should
be monitored after arm ischemia for 30 minutes produced
by a tourniquet, in order to establish if such values decrease
until they become undetectable (47). Re-operation is
characterized by a substantial risk of inferior laryngeal
nerve injury; therefore, it is indicated only when the
recurrence is symptomatic, with high urinary calcium loss
and significant bone mass reduction.
In the case of cervical or mediastinal recurrence, the
surgical option is to remove the entire residual parathyroid
tissue and then to perform heterotopic autologous transplan-
tation. This technique carries a low risk of persistent HPT.
After TPTX with autograft, recurrence rates of 38% and 36%,
respectively, were reported by Helmann et al. (20) and Kivlen et
al. (43). However, TPTX without autograft is a possible choice
for these patients after adequate informed consent, as they will
need lifelong substitutive therapy with calcium and vitamin D.
If recurrence is diagnosed at the graft site, the removal of
transplanted tissue is the treatment of choice, even if the
best results cannot be always achieved; a 42% cure rate was
reported by Kivlen et al. (43).
Recently, a pharmacologic approach was proposed for the
cure of sporadic primary or secondary HPT, with the
introduction of calcimimetics, a new class of drugs with the
property of reducing PTH release (48,49). The efficacy of
these molecules in HPT/MEN1, and particularly in its
recurrence, needs to be proven through further studies and
longer follow-up.
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